|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC38A3 |
Gene summary for SLC38A3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC38A3 | Gene ID | 10991 |
| Gene name | solute carrier family 38 member 3 | |
| Gene Alias | G17 | |
| Cytomap | 3p21.31 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q99624 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10991 | SLC38A3 | HCC1_Meng | Human | Liver | HCC | 1.42e-84 | 4.42e-01 | 0.0246 |
| 10991 | SLC38A3 | HCC1 | Human | Liver | HCC | 9.08e-16 | 2.46e+00 | 0.5336 |
| 10991 | SLC38A3 | HCC2 | Human | Liver | HCC | 7.06e-23 | 3.03e+00 | 0.5341 |
| 10991 | SLC38A3 | S014 | Human | Liver | HCC | 4.73e-38 | 1.92e+00 | 0.2254 |
| 10991 | SLC38A3 | S015 | Human | Liver | HCC | 2.03e-42 | 2.41e+00 | 0.2375 |
| 10991 | SLC38A3 | S016 | Human | Liver | HCC | 5.35e-64 | 2.31e+00 | 0.2243 |
| 10991 | SLC38A3 | S028 | Human | Liver | HCC | 2.08e-14 | 6.29e-01 | 0.2503 |
| 10991 | SLC38A3 | S029 | Human | Liver | HCC | 4.24e-19 | 8.63e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003166722 | Liver | HCC | response to nutrient levels | 276/7958 | 474/18723 | 2.30e-12 | 1.08e-10 | 276 |
| GO:007149622 | Liver | HCC | cellular response to external stimulus | 191/7958 | 320/18723 | 3.40e-10 | 1.13e-08 | 191 |
| GO:003166812 | Liver | HCC | cellular response to extracellular stimulus | 149/7958 | 246/18723 | 7.35e-09 | 1.86e-07 | 149 |
| GO:004259421 | Liver | HCC | response to starvation | 121/7958 | 197/18723 | 6.08e-08 | 1.28e-06 | 121 |
| GO:003166912 | Liver | HCC | cellular response to nutrient levels | 130/7958 | 215/18723 | 7.52e-08 | 1.51e-06 | 130 |
| GO:007121421 | Liver | HCC | cellular response to abiotic stimulus | 183/7958 | 331/18723 | 1.59e-06 | 2.26e-05 | 183 |
| GO:010400421 | Liver | HCC | cellular response to environmental stimulus | 183/7958 | 331/18723 | 1.59e-06 | 2.26e-05 | 183 |
| GO:000926712 | Liver | HCC | cellular response to starvation | 94/7958 | 156/18723 | 5.61e-06 | 6.95e-05 | 94 |
| GO:015010411 | Liver | HCC | transport across blood-brain barrier | 50/7958 | 87/18723 | 3.42e-03 | 1.55e-02 | 50 |
| GO:001023211 | Liver | HCC | vascular transport | 50/7958 | 88/18723 | 4.69e-03 | 2.02e-02 | 50 |
| GO:00075651 | Liver | HCC | female pregnancy | 99/7958 | 193/18723 | 8.24e-03 | 3.23e-02 | 99 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC38A3 | SNV | Missense_Mutation | novel | c.1433N>A | p.Gly478Asp | p.G478D | Q99624 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| SLC38A3 | SNV | Missense_Mutation | rs759842322 | c.205N>A | p.Gly69Arg | p.G69R | Q99624 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-EW-A1PH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| SLC38A3 | insertion | Frame_Shift_Ins | novel | c.795_796insAGAAAGCGGGCAGCGGGTCTCCTGGGGGAGTTCCCTGTCAT | p.Gln266ArgfsTer114 | p.Q266Rfs*114 | Q99624 | protein_coding | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| SLC38A3 | insertion | Frame_Shift_Ins | novel | c.73_74insACTCAAATGGTGTTAAGCCTGTAGGTTTTCCTCATTTC | p.Val25AspfsTer92 | p.V25Dfs*92 | Q99624 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| SLC38A3 | deletion | Frame_Shift_Del | novel | c.146delN | p.Leu49HisfsTer55 | p.L49Hfs*55 | Q99624 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| SLC38A3 | SNV | Missense_Mutation | novel | c.548N>G | p.Ser183Trp | p.S183W | Q99624 | protein_coding | deleterious(0.02) | possibly_damaging(0.856) | TCGA-DS-A0VM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| SLC38A3 | SNV | Missense_Mutation | novel | c.162C>A | p.Ser54Arg | p.S54R | Q99624 | protein_coding | tolerated(0.46) | benign(0.091) | TCGA-MU-A5YI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| SLC38A3 | SNV | Missense_Mutation | novel | c.79N>G | p.Thr27Ala | p.T27A | Q99624 | protein_coding | tolerated(0.62) | benign(0) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| SLC38A3 | SNV | Missense_Mutation | novel | c.1220A>G | p.His407Arg | p.H407R | Q99624 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR |
| SLC38A3 | SNV | Missense_Mutation | rs866210794 | c.134G>A | p.Gly45Asp | p.G45D | Q99624 | protein_coding | tolerated(0.22) | benign(0) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 10991 | SLC38A3 | TRANSPORTER | 178101351 | |||
| 10991 | SLC38A3 | TRANSPORTER | 178101352 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |